Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/4/2018
SIETES contiene 92261 citas

 
 
 1 a 20 de 115 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016;176:1531-8. [Ref.ID 100584]
3. Cita con resumen
Anónimo. Trimetazidina: se recuerda que actualmente su única indicación autorizada es el tratamiento de la angina de pecho . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:19 de julio. [Ref.ID 100502]
4. Cita con resumen
Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]
5. Cita con resumen
McCarthy M. US Senate committee launches investigation into drug pricing. BMJ 2015;351:h5989. [Ref.ID 99683]
6. Cita con resumen
Anónimo. Incontinences urinaires d'origine médicamenteuse. Prescrire 2015;35:271-4. [Ref.ID 99126]
7. Cita con resumen
Hyde R. Germany launches investigation into human trials scandal. Lancet 2013;382:115-6. [Ref.ID 95826]
8. Cita con resumen
Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013;173:611-2. [Ref.ID 95286]
9. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
10. Cita con resumen
Anónimo. Ranolazine: hallucinations. Prescrire 2012;32:917. [Ref.ID 94200]
11. Cita con resumen
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kigfield PD, Krumholz HM, Kwong RYK, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Sabik JF, Shaw LJ, Sikkema JD, Smith Jr CR, Smith Jr SC, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;60:e44-e164. [Ref.ID 93287]
12. Cita con resumen
Anónimo. Ranolazine and hallucination. WHO Pharmaceuticals Newsletter 2012;2:abril. [Ref.ID 92616]
13. Cita con resumen
Anónimo. Buflomedil-containing medicines. WHO Pharmaceuticals Newsletter 2011;3:5. [Ref.ID 90978]
14. Cita con resumen
Anónimo. Pusillanimité. Prescrire 2011;31:5. [Ref.ID 89984]
15. Cita con resumen
Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010;33:713-26. [Ref.ID 89267]
16. Cita con resumen
Anónimo. Ulcérations douloureuses chroniques liées au nicorandil: le vagin aussi. Prescrire 2010;30:514. [Ref.ID 88787]
18. Cita con resumen
De Backer TLM, Stichele RHV, Van Bortel LM. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. Drug Saf 2009;32:283-91. [Ref.ID 85762]
19. Cita con resumen
De Backer T, Stichele RV, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ 2009;338:703. [Ref.ID 85532]
20. Cita con resumen
Kildemoes HW, Stovring H, Andersen M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol 2008;66:885-95. [Ref.ID 85066]
Seleccionar todas
 
 1 a 20 de 115 siguiente >>